4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-benzamide | 881676-19-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-benzamide
• 英文别名: 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-4-ylpyrimidin-2-yl)amino]phenyl]benzamide
• CAS: 881676-19-3
• 化学式: C₂₉H₃₁N₇O
• 分子量: 493.611
• InChiKey: BYMYDYHSVGWQTQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  37
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  86.3
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Pyrimidine Derivatives
  申请人：Klebl Bert

  公开号：US20080187575A1

  公开（公告）日：2008-08-07

  The present invention relates to pyrimidine derivatives, methods for their synthesis, and the use of said pyrimidine derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferation disorders, cancer, leukemia, erectile dysfunction, cardiovascular diseases and disorders, inflammatory diseases, transplant rejection, immunological diseases, neuroimmunological diseases, autoimmune diseases, infective diseases including opportunistic infections, prion diseases and/or neuro-degeneration. Furthermore, the present invention relates to pharmaceutical compositions containing at least one pyrimidine derivative and/or pharmaceutically acceptable salts thereof as an active ingredient together with at least one pharmaceutically acceptable carrier, excipient or diluents as well as to methods for prophylaxis and/or treatment of the above-mentioned diseases and disorders.

  本发明涉及嘧啶衍生物，其合成方法，以及所述嘧啶衍生物作为药用活性剂的用途，特别是用于预防和/或治疗细胞增殖紊乱、癌症、白血病、勃起功能障碍、心血管疾病和紊乱、炎症性疾病、移植排斥、免疫性疾病、神经免疫性疾病、自身免疫性疾病、感染性疾病包括机会性感染、朊病和/或神经退行性疾病。此外，本发明涉及含有至少一种嘧啶衍生物和/或其药用可接受盐作为活性成分的药物组合物，以及用于预防和/或治疗上述疾病和紊乱的方法。
• PYRIMIDINE DERIVATIVES
  申请人：GPC Biotech AG

  公开号：EP1786781A2

  公开（公告）日：2007-05-23
• [EN] PYRIMIDINE DERIVATIVES<br/>[FR] DERIVES DE PYRIMIDINE
  申请人：GPC BIOTECH AG

  公开号：WO2006021458A2

  公开（公告）日：2006-03-02

  The present invention relates to pyrimidine derivatives, methods for their synthesis, and the use of said pyrimidine derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferation disorders, cancer, leukemia, erectile dysfunction, cardiovascular diseases and disorders, inflammatory diseases, transplant rejection, immunological diseases, neuroimmunological diseases, autoimmune diseases, infective diseases including opportunistic infections, prion diseases and/or neuro-degeneration. Furthermore, the present invention relates to pharmaceutical compositions containing at least one pyrimidine derivative and/or pharmaceutically acceptable salts thereof as an active ingredient together with at least one pharmaceutically acceptable carrier, excipient or diluents as well as to methods for prophylaxis and/or treatment of the above-mentioned diseases and disorders.
• [EN] METHOD FOR EXTRACTING SUBSTANCES WITH ANTINEOPLASIC ACTIVITY FROM THE CEROPEGIA FUSCA PLANT, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[ES] MÉTODO DE EXTRACCIÓN DE SUSTANCIAS DE LA PLANTA CEROPEGIA FUSCA CON ANTICIDAD ANTINEOPLÁSICA Y COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN.<br/>[FR] PROCÉDÉ D'EXTRACTION DE SUBSTANCES DE LA PLANTECEROPEGIA FUSCA PRÉSENTANT UNE ACTIVITÉ ANTINÉOPLASIQUE ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：LUCIANO REVERON E HIJOS S L

  公开号：WO2008034920A1

  公开（公告）日：2008-03-27

  [EN] Method for extracting substances with antineoplasic activity from the Ceropegia fusca plant, and pharmaceutical compositions containing them. The method involves macerating the fresh plant with ethanol at 25°C; evaporating the solvent using a vacuum and at a temperature of 40°C; extracting the remaining aqueous extract in countercurrent and at reflux using CH₂CI₂ and subsequently n-butanol. The component substances of the extract are purified by means of silica gel column chromatography using the n-hexane:CHCI₃:acetone system in the ratio 1:1:1 as eluents. The extract obtained from Ceropegia fusca has antineoplasic components and can be used in pharmaceutical compositions containing said extract for these purposes.
  [FR] L'invention concerne un procédé d'extraction de substances de la planta Ceropegia fusca présentant une activité antinéoplasique et des compositions pharmaceutiques les contenant. Ledit procédé consiste à faire macérer la plante à froid avec de l'éthanol à 25°C; à évaporer le dissolvant sous vide et à une température de 40 °C; et à extraire l'extrait aqueux restant à contre-courant et à reflux à l'aide de CH₂CI₂ et, ultérieurement, de n-butanol. Les substances composant l'extrait sont purifiées par chromatographie sur colonne de gel de silice, en utilisant comme éluants du système n-hexane:CHCI₃:acétone selon la proportion 1 :1 :1. L'extrait de Ceropegia fusca obtenu contient des composants antinéoplasiques et peut être utilisé dans des compositions pharmaceutiques contenant ledit extrait à cette fin.
  [ES] Método de extracción de sustancias de la planta Ceropegia fusca con actividad antineoplásica y composiciones farmacéuticas que las contienen. El método comprende la maceración de la planta en fresco con etanol a 25 °C; evaporación del disolvente mediante vacío y a una temperatura de 40 °C; extracción del extracto acuoso restante en contracorriente y a reflujo utilizando CH₂CI₂ y, posteriomente, n-butanol. Las sustancias componentes del extracto se purifican medante cromatografía en columna de gel de sílice utilizando como eluyentes del sistema n-hexano:CHCI₃:acetona en la proporción 1 :1 :1. El extracto obtenido de Ceropegia fusca tiene componentes antineoplásicos y pueden ser utilizado en composiciones farmacéuticas que contienen dicho extracto para estos fines.